source
- Roche touts strong Phase 3 track record while trimming pipeline amid peer setbacksRoche's chief executive Thomas Schinecker highlighted the company's high success rate in Phase 3 trials, positioning it as a competitive advantage. The comment accompanied an announcement that Roc…
- AbbVie’s lutikizumab meets primary endpoint in Phase 3 hidradenitis trial but falls short of market expectationsAbbVie announced that its experimental drug lutikizumab achieved its primary goal in a Phase 3 study of hidradenitis suppurativa, a chronic inflammatory skin disease. The Intrepid trial enrolled a…